Novavax, Inc.
(NASDAQ : NVAX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.21%239.821.3%$789.32m
MRNAModerna, Inc. 4.90%68.370.0%$722.18m
IMMUImmunomedics, Inc. -0.09%85.2311.0%$688.57m
NVAXNovavax, Inc. 9.20%111.8696.5%$611.95m
GILDGilead Sciences, Inc. -0.52%61.931.0%$572.01m
ILMNIllumina, Inc. 4.86%300.223.5%$527.35m
REGNRegeneron Pharmaceuticals, Inc. 0.99%563.002.7%$429.30m
BIIBBiogen, Inc. -0.11%269.751.6%$332.79m
VRTXVertex Pharmaceuticals, Inc. -0.04%263.021.9%$328.11m
ALXNAlexion Pharmaceuticals, Inc. 1.26%113.432.0%$281.73m
SRNESorrento Therapeutics, Inc. 3.05%9.471.5%$253.86m
EXASEXACT Sciences Corp. 4.26%98.3320.7%$241.94m
VXRTVaxart, Inc. 5.37%7.260.0%$209.24m
SGENSeattle Genetics, Inc. 1.76%182.596.0%$207.47m
MNTAMomenta Pharmaceuticals, Inc. 0.06%52.423.0%$197.96m

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.